UC Davis Cancer Center is the only California institution to receive a share of $6 million in
grants awarded by the National Institutes of Health and five major drug makers to improve patient participation
in early clinical trials.
UC Davis Cancer Center was awarded funding for a $1.1 million proposal aimed at overcoming barriers to
participation in clinical trials, the studies that determine whether a new therapy is safe and effective.
Overall, only 3 percent of cancer patients participate in trials, a rate that has not improved in more
than two decades. Low participation rates prolong drug development and delay patient access to potentially
effective new agents.
"We hope our study will play a part in accelerating the pace of clinical-trials research nationally,"
said Primo N. Lara, Jr., assistant professor of medicine at UC Davis Cancer Center and principal investigator
of the barriers study.